Policy | March 14, 2022
Draft policy on medical devices released
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
Subscribe To Our Newsletter & Stay Updated
